Proactive Investors - Run By Investors For Investors

Tiziana's Foralumab can be biggest disruptor to medical industry 'in a decade'

Chairman and founder of Tiziana Life Sciences plc (LON:TILS) Gabriele Cerrone introduces Proactive London's Andrew Scott to their two lead programmes - one focused on liver cancer and the other on autoimmune diseases.

Tiziana's recently completed two critical clinical trials with data expected in the coming weeks.

Last November it dual-listed on NASDAQ and in the process raised £3.42mln.

Meet Yellow Cake PLC, Avation PLC, Manolete Partners PLC and Crossword Cybersecurity Plc at our event, London , 05 September 2019. Register here »
View full TILS profile View Profile

Tiziana Life Sciences Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use